[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 37 of about 37
1. Yu XC, Xu M, Song RX, Xu SF: Marginal resection for osteosarcoma with effective preoperative chemotherapy. Orthop Surg; 2009 Aug;1(3):196-202
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Marginal resection for osteosarcoma with effective preoperative chemotherapy.
  • OBJECTIVE: To present the clinical results of marginal resection with effective preoperative chemotherapy for treatment of osteosarcoma.
  • METHODS: Thirty-eight patients (20 male and 18 female, average age 17 years), underwent marginal resection after confirmation of effective preoperative chemotherapy between 1999 and 2008 and the results were analyzed retrospectively.
  • The distal femur was involved in 22 cases, proximal tibia in 11, proximal humerus in 4, and proximal fibula in 1.
  • Twenty-nine patients were treated with the DIA, and 9 with the MMIA protocol.
  • RESULTS: All patients received effective preoperative chemotherapy.
  • At a median follow-up of 52 months, local recurrence had developed in one patient (2.6% local recurrence rate).
  • Pulmonary metastases developed in 9 patients (23.7%).
  • Five patients died of metastases, one died of intracranial hemorrhage due to thrombocytopenia caused by postoperative chemotherapy.
  • CONCLUSIONS: With careful preoperative evaluation and effective preoperative chemotherapy marginal resection of osteosarcoma can produce good results.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Bone Neoplasms / surgery. Orthopedic Procedures / methods. Osteosarcoma / surgery. Preoperative Care / methods
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. China / epidemiology. Disease-Free Survival. Female. Femur. Fibula. Follow-Up Studies. Humans. Humerus. Male. Prognosis. Retrospective Studies. Survival Rate / trends. Tibia. Time Factors

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2009 Tianjin Hospital and Blackwell Publishing Asia Pty Ltd.
  • (PMID = 22009842.001).
  • [ISSN] 1757-7861
  • [Journal-full-title] Orthopaedic surgery
  • [ISO-abbreviation] Orthop Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


2. Blanco CE, Zhan WZ, Fang YH, Sieck GC: Exogenous testosterone treatment decreases diaphragm neuromuscular transmission failure in male rats. J Appl Physiol (1985); 2001 Mar;90(3):850-6
Hazardous Substances Data Bank. TESTOSTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exogenous testosterone treatment decreases diaphragm neuromuscular transmission failure in male rats.
  • The effect of chronic exogenous testosterone (T) treatment on neuromuscular transmission in the diaphragm (Dia) muscle of adult male rats was determined.
  • The contribution of neuromuscular transmission failure (NTF) to Dia fatigue was evaluated by superimposing intermittent direct muscle stimulation on repetitive nerve stimulation of isometric contraction in vitro.
  • T treatment significantly reduced the contribution of NTF to Dia fatigue by approximately 20% (P < 0.001).
  • Fiber type-specific effects on NTF were determined by measuring Dia fiber glycogen levels subsequent to repetitive nerve or muscle stimulation.
  • T treatment had no effect on glycogen depletion in Dia type I and IIa fibers regardless of stimulation route.
  • In the control group, type IIx fibers demonstrated significantly less glycogen depletion after nerve stimulation compared with direct muscle stimulation (P < 0.05), suggesting the presence of NTF.
  • In contrast, T treatment increased glycogen depletion of type IIx fibers during nerve stimulation to levels similar to those after direct muscle stimulation.
  • These data indicate that testosterone treatment substantially improves neuromuscular transmission in the Dia.
  • [MeSH-minor] Animals. Drug Implants. Electric Stimulation. Glycogen / metabolism. In Vitro Techniques. Isometric Contraction / drug effects. Isometric Contraction / physiology. Male. Muscle Fatigue. Muscle Fibers, Skeletal / physiology. Muscle, Skeletal / drug effects. Muscle, Skeletal / innervation. Muscle, Skeletal / physiology. Rats. Rats, Sprague-Dawley. Synaptic Transmission / drug effects

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11181592.001).
  • [ISSN] 8750-7587
  • [Journal-full-title] Journal of applied physiology (Bethesda, Md. : 1985)
  • [ISO-abbreviation] J. Appl. Physiol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL-34817; United States / NHLBI NIH HHS / HL / HL-37680; United States / NHLBI NIH HHS / HL / HL-59904
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Implants; 3XMK78S47O / Testosterone; 9005-79-2 / Glycogen
  •  go-up   go-down


3. de Paula CD, Sampaio JH, Cardoso DR, Sampaio RN: [A comparative study between the efficacy of pentamidine isothionate given in three doses for one week and N-methil-glucamine in a dose of 20mgSbV/day for 20 days to treat cutaneous leishmaniasis]. Rev Soc Bras Med Trop; 2003 May-Jun;36(3):365-71
Hazardous Substances Data Bank. PENTAMIDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Estudo comparativo da efic cia de isotionato de pentamidina administrada em tr s doses durante uma semana e de N-metil-glucamina 20mgSbV/kg/dia durante 20 dias para o tratamento da forma cut nea da leishmaniose tegumentar americana.
  • In our study pentamidine was as effective as antimonial for the treatment of american cutaneous leishmaniasis.
  • It proved to be a safer drug considering heart toxicity.
  • Moreover, it requires less time to complete the treatment.
  • [MeSH-major] Antiprotozoal Agents / administration & dosage. Leishmaniasis, Cutaneous / drug therapy. Meglumine / administration & dosage. Organometallic Compounds / administration & dosage. Pentamidine / administration & dosage

  • Genetic Alliance. consumer health - Leishmaniasis.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12908038.001).
  • [ISSN] 0037-8682
  • [Journal-full-title] Revista da Sociedade Brasileira de Medicina Tropical
  • [ISO-abbreviation] Rev. Soc. Bras. Med. Trop.
  • [Language] por
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Antiprotozoal Agents; 0 / Organometallic Compounds; 673LC5J4LQ / Pentamidine; 6HG8UB2MUY / Meglumine; 75G4TW236W / meglumine antimoniate
  •  go-up   go-down


Advertisement
4. Penumathsa SV, Thirunavukkarasu M, Samuel SM, Zhan L, Maulik G, Bagchi M, Bagchi D, Maulik N: Niacin bound chromium treatment induces myocardial Glut-4 translocation and caveolar interaction via Akt, AMPK and eNOS phosphorylation in streptozotocin induced diabetic rats after ischemia-reperfusion injury. Biochim Biophys Acta; 2009 Jan;1792(1):39-48
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Niacin bound chromium treatment induces myocardial Glut-4 translocation and caveolar interaction via Akt, AMPK and eNOS phosphorylation in streptozotocin induced diabetic rats after ischemia-reperfusion injury.
  • Rats were randomized into: Control (Con); Diabetic (Dia) and Diabetic rats fed with NBC (Dia+NBC).
  • After 30 days of treatment, the isolated hearts were subjected to 30 min of global ischemia followed by 2 h of reperfusion.
  • NBC treatment demonstrated significant increase in left ventricular functions and significant reduction in infarct size and cardiomyocyte apoptosis in Dia+NBC compared with Dia.
  • Increased Glut-4 translocation to the lipid raft fractions was also observed in Dia+NBC compared to Dia.
  • Reduced Cav-1 and increased Cav-3 expression along with phosphorylation of Akt, eNOS and AMPK might have resulted in increased Glut-4 translocation in Dia+NBC.
  • [MeSH-major] Cardiotonic Agents / pharmacology. Chromium / pharmacology. Diabetes Mellitus, Experimental / drug therapy. Glucose Transporter Type 4 / metabolism. Myocardial Reperfusion Injury / drug therapy. Myocardial Reperfusion Injury / metabolism. Niacin / pharmacology
  • [MeSH-minor] AMP-Activated Protein Kinases / metabolism. Animals. Apoptosis / drug effects. Biological Transport, Active / drug effects. Caveolae / drug effects. Caveolae / metabolism. Caveolins / metabolism. In Vitro Techniques. Male. Myocardium / metabolism. Myocytes, Cardiac / drug effects. Myocytes, Cardiac / pathology. Nitric Oxide Synthase Type III / metabolism. Phosphorylation. Proto-Oncogene Proteins c-akt / metabolism. Rats. Rats, Sprague-Dawley

  • Hazardous Substances Data Bank. NICOTINIC ACID .
  • Hazardous Substances Data Bank. CHROMIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19027847.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cardiotonic Agents; 0 / Caveolins; 0 / Glucose Transporter Type 4; 0 / Slc2a4 protein, rat; 0R0008Q3JB / Chromium; 2679MF687A / Niacin; EC 1.14.13.39 / Nitric Oxide Synthase Type III; EC 1.14.13.39 / Nos3 protein, rat; EC 2.7.11.1 / AMP-Activated Protein Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


5. Fournier M, Huang ZS, Li H, Da X, Cercek B, Lewis MI: Insulin-like growth factor I prevents corticosteroid-induced diaphragm muscle atrophy in emphysematous hamsters. Am J Physiol Regul Integr Comp Physiol; 2003 Jul;285(1):R34-43
MedlinePlus Health Information. consumer health - Steroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to evaluate whether recombinant human insulin-like growth factor I (rhIGF-I) could attenuate or prevent diaphragm (DIA) fiber atrophy with corticosteroid (CS) administration to emphysematous (EMP) hamsters.
  • DIA muscle IGF-I responses to CS administration with and without exogenous rhIGF-I administration were evaluated.
  • After 4 wk, the DIA was analyzed histochemically and biochemically (IGF-I mRNA levels by RT-PCR and endogenous and exogenous IGF-I peptide levels immunochemically).
  • DIA weight was reduced with T but preserved with rhIGF-I infusion.
  • DIA fiber proportions were similar among the groups.
  • The cross-sectional areas of types I, IIa, and IIx fibers were reduced (17 to 31%) with T administration but unchanged with rhIGF-I infusion.
  • DIA IGF-I mRNA levels were similar across all groups.
  • By contrast, the endogenous DIA IGF-I levels were reduced (41%) in the EMP-T-IGF-I animals.
  • Total DIA IGF-I levels (endogenous + exogenous) were still significantly reduced.
  • IGF-I immunoreactivity confirmed this reduction in all DIA fibers.
  • We conclude that DIA fiber atrophy with T was completely prevented by exogenous rhIGF-I administration.
  • This effect was likely mediated by the pharmacological influences of exogenously administered rhIGF-I.
  • Reduced endogenous IGF-I levels in the DIA likely reflect a negative-feedback influence.
  • These results may have important clinical implications for treatment options to offset the adverse effects of CS on the respiratory muscles in patients with chronic lung disorders.
  • [MeSH-major] Adrenal Cortex Hormones / pharmacology. Diaphragm / pathology. Emphysema / drug therapy. Insulin-Like Growth Factor I / pharmacology. Muscular Atrophy / prevention & control

  • MedlinePlus Health Information. consumer health - Emphysema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12689851.001).
  • [ISSN] 0363-6119
  • [Journal-full-title] American journal of physiology. Regulatory, integrative and comparative physiology
  • [ISO-abbreviation] Am. J. Physiol. Regul. Integr. Comp. Physiol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL-47537
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / RNA, Messenger; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


6. Uro-Coste E, Ssi-Yan-Kai G, Guilbeau-Frugier C, Boetto S, Bertozzi AI, Sevely A, Lolmede K, Delisle MB: Desmoplastic infantile astrocytoma with benign histological phenotype and multiple intracranial localizations at presentation. J Neurooncol; 2010 May;98(1):143-9
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic infantile astrocytoma with benign histological phenotype and multiple intracranial localizations at presentation.
  • Desmoplastic infantile astrocytoma (DIA) and desmoplastic infantile ganglioglioma (DIG) are rare intracranial tumors that mostly occur in the first 2 years of life and involve superficial cerebral cortex.
  • We report an original observation of a desmoplastic infantile astrocytoma in a 5-year-old boy with multiple localizations on initial presentation, including the unusual subtentorial region.
  • Adjuvant chemotherapy was applied, with shrinkage of lesions.
  • DIA and DIG are more generally unifocal at initial presentation.
  • Previously, only five cases of DIG/DIA located in two or more separate locations have been published.
  • We report the sixth, and first noninfantile, case of DIA/DIG with multifocal initial presentation.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology
  • [MeSH-minor] Brain / diagnostic imaging. Brain / pathology. Child, Preschool. Humans. Magnetic Resonance Imaging / methods. Male. Radiography. Tomography Scanners, X-Ray Computed

  • Genetic Alliance. consumer health - Desmoplastic Infantile Astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 2000 Jan;16(1):8-14 [10672423.001]
  • [Cites] Childs Nerv Syst. 2003 Jun;19(5-6):292-7 [12750935.001]
  • [Cites] Childs Nerv Syst. 2002 Oct;18(9-10):463-7 [12382166.001]
  • [Cites] Mod Pathol. 2001 Jul;14(7):720-6 [11455006.001]
  • [Cites] Australas Radiol. 2005 Oct;49(5):433-7 [16174188.001]
  • [Cites] Mod Pathol. 1997 Sep;10(9):945-51 [9310960.001]
  • [Cites] Pediatr Radiol. 2006 Jun;36(6):541-5 [16552586.001]
  • [Cites] Neurosurgery. 2003 Oct;53(4):979-83; discussion 983-4 [14519230.001]
  • [Cites] Pediatr Neurosurg. 2002 Jan;36(1):29-32 [11818743.001]
  • [Cites] Pediatr Radiol. 1995;25(7):540-3 [8545186.001]
  • [Cites] Surg Neurol. 2007 Sep;68(3):304-8; discussion 308 [17719974.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):275-81 [8293187.001]
  • [Cites] Cancer. 1984 Dec 1;54(11):2505-12 [6498740.001]
  • [Cites] Neurosurgery. 1994 Apr;34(4):583-9; discussion 589 [8008154.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1515-22 [12409729.001]
  • [Cites] Neurosurg Rev. 2009 Jul;32(3):369-74; discussion 374 [19280238.001]
  • [Cites] J Neurooncol. 2006 Feb;76(3):271-5 [16205962.001]
  • [Cites] Pediatr Blood Cancer. 2005 Dec;45(7):986-90 [15702481.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9809-17 [17047041.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Sep;67(9):911-20 [18716553.001]
  • [Cites] Acta Neuropathol. 1993;85(2):199-204 [8442411.001]
  • [Cites] J Neurosurg. 1987 Jan;66(1):58-71 [3097276.001]
  • [Cites] Ann Diagn Pathol. 2004 Oct;8(5):280-3 [15494934.001]
  • (PMID = 20012157.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Kato M, Yano H, Okumura A, Shinoda J, Sakai N, Shimokawa K: A non-infantile case of desmoplastic infantile astrocytoma. Childs Nerv Syst; 2004 Jul;20(7):499-501
Genetic Alliance. consumer health - Desmoplastic Infantile Astrocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A non-infantile case of desmoplastic infantile astrocytoma.
  • CASE REPORT: We describe a very rare non-infantile case of desmoplastic infantile astrocytoma (DIA).
  • Its histopathological features were typical of DIA.
  • Neither radiotherapy nor chemotherapy was used postoperatively.
  • The patient developed normally and had been doing well for 12 months after surgery without tumor recurrence.
  • [MeSH-major] Astrocytoma / pathology. Cerebellar Neoplasms / pathology
  • [MeSH-minor] Child. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry / methods. Magnetic Resonance Imaging / methods. Male. Microscopy, Electron, Transmission / methods. Motor Cortex / pathology. Motor Cortex / surgery. Neurosurgical Procedures. Staining and Labeling / methods. Tomography, X-Ray Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 2000 Jan;16(1):8-14 [10672423.001]
  • [Cites] Clin Neurol Neurosurg. 1995 Feb;97(1):32-5 [7788970.001]
  • [Cites] Childs Nerv Syst. 1995 Oct;11(10):559-67 [8556721.001]
  • [Cites] J Neurooncol. 2002 Aug;59(1):63-9 [12222839.001]
  • [Cites] Histopathology. 1992 Jul;21(1):43-9 [1634201.001]
  • [Cites] Pathol Int. 2000 Sep;50(9):744-9 [11012989.001]
  • [Cites] Hum Pathol. 1992 Dec;23(12):1402-9 [1468778.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):173-9 [2354404.001]
  • [Cites] Cancer. 1979 Nov;44(5):1839-52 [498051.001]
  • [Cites] Cancer. 1984 Dec 1;54(11):2505-12 [6498740.001]
  • [Cites] J Korean Med Sci. 1998 Aug;13(4):440-4 [9741553.001]
  • [Cites] Acta Neuropathol. 1993;85(2):199-204 [8442411.001]
  • [Cites] Cancer Res. 1987 Jul 1;47(13):3515-22 [3555773.001]
  • [Cites] J Neurosurg. 1987 Jan;66(1):58-71 [3097276.001]
  • (PMID = 14997329.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  •  go-up   go-down


8. Yoshino A, Katayama Y, Yokoyama T, Watanabe T, Ogino A, Ota T, Komine C, Fukushima T, Kusama K: Therapeutic implications of interferon regulatory factor (IRF)-1 and IRF-2 in diffusely infiltrating astrocytomas (DIA): response to interferon (IFN)-beta in glioblastoma cells and prognostic value for DIA. J Neurooncol; 2005 Sep;74(3):249-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic implications of interferon regulatory factor (IRF)-1 and IRF-2 in diffusely infiltrating astrocytomas (DIA): response to interferon (IFN)-beta in glioblastoma cells and prognostic value for DIA.
  • Furthermore, we attempted to determine whether or not IRF-1 and IRF-2 act as additional prognostic indicators in diffusely infiltrating astrocytomas (DIA).
  • We first assessed the cytotoxic effects of IFN-beta based on a cell growth study and modified MTT assay, and then quantified the apoptosis using a sandwich enzyme immunoassay following IFN-beta treatment in the cell lines, U-87MG, T98G, and A-172.
  • Furthermore, we assessed the expression of type I IFN receptor, IRF-1, and IRF-2 using immunohistochemical techniques in 63 DIA (15 of WHO grade II, 18 of grade III, and 30 of grade IV), and analyzed their impact on prognosis.
  • An increase in apoptosis was apparent after 48 h of IFN-beta treatment (1 x 10(4) IU/ml) in T98G but not in U-87MG or A-172.
  • IFN-beta treatment for 6 h significantly enhanced the expression of IRF-1 in all three cell lines.
  • While minimal processing of caspase-8 was noted in the three cell lines throughout the experiment, caspase-9 activation was observed in the apoptosis-detected T98G after 48 h of treatment, as indicated by a 1.33-fold increase (P=0.037).
  • On the other hand, the IRF-1 LI and IRF-1/IRF-2 LI ratio were greater in low-grade DAI, and were negatively correlated with the histopathological grade in DIA (P=0.017 and P=0.001, respectively).
  • Furthermore, the IRF-1/IRF-2 LI ratio was negatively correlated with the MIB-1 LI in DIA (P=0.004), and represented an independent and most powerful determinant of overall survival compared to other conventional prognostic factors (P=0.018).
  • However, the relation was not statistically significant when only patients with high-grade DIA were assessed.
  • Furthermore, the IRF-1/IRF-2 LI ratio may reflect the proliferative state of DIA and constitute an important prognostic marker in DIA.
  • Thus, IRF-1 and IRF-2 could represent one of the therapeutic target sites for the regulation of cell growth in DIA.
  • [MeSH-major] Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Glioblastoma / drug therapy. Interferon Regulatory Factor-1 / metabolism. Interferon Regulatory Factor-2 / metabolism. Interferon-beta / pharmacology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Apoptosis / physiology. Blotting, Western. Caspases / drug effects. Caspases / metabolism. Cell Line, Tumor. Cell Survival / drug effects. Dose-Response Relationship, Drug. Enzyme Activation / drug effects. Enzyme Activation / physiology. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Receptors, Interferon / metabolism

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurochir (Wien). 1994;127(1-2):55-9 [7942182.001]
  • [Cites] J Biol Chem. 1998 Jan 2;273(1):194-9 [9417064.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;45(3):199-206 [10663637.001]
  • [Cites] Science. 1993 Feb 12;259(5097):971-4 [8438157.001]
  • [Cites] Nature. 1991 Jun 6;351(6326):453-6 [2046748.001]
  • [Cites] Cell. 1998 Sep 18;94(6):739-50 [9753321.001]
  • [Cites] J Biol Chem. 1992 Mar 15;267(8):5017-20 [1371992.001]
  • [Cites] Cancer Res. 2003 Jan 15;63(2):513-21 [12543810.001]
  • [Cites] J Biol Chem. 1998 Oct 23;273(43):28378-83 [9774464.001]
  • [Cites] Oncogene. 1994 Nov;9(11):3313-20 [7936656.001]
  • [Cites] Nature. 1996 Aug 29;382(6594):816-8 [8752276.001]
  • [Cites] Cancer Res. 2000 Oct 15;60(20):5673-80 [11059759.001]
  • [Cites] J Cell Biol. 1999 Jan 25;144(2):281-92 [9922454.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1312-6 [9721091.001]
  • [Cites] Cell. 1998 Aug 7;94(3):339-52 [9708736.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):7133-41 [11156422.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1309-12 [9721092.001]
  • [Cites] Annu Rev Cell Dev Biol. 1999;15:269-90 [10611963.001]
  • [Cites] Toxicol Lett. 1998 Dec 28;102-103:121-9 [10022243.001]
  • [Cites] J Neurooncol. 2003 Jan;61(2):171-6 [12622456.001]
  • [Cites] J Biol Chem. 1999 Feb 19;274(8):5053-60 [9988752.001]
  • [Cites] Cell. 1997 Nov 14;91(4):479-89 [9390557.001]
  • [Cites] Science. 1991 Jul 5;253(5015):49-53 [1905840.001]
  • [Cites] Trends Cell Biol. 1996 Jul;6(7):245-8 [15157443.001]
  • [Cites] Biochimie. 1998 Aug-Sep;80(8-9):641-50 [9865486.001]
  • [Cites] Eur Cytokine Netw. 1998 Dec;9(4):619-31 [9889406.001]
  • [Cites] Immunol Today. 1988 Dec;9(12):393-400 [2475121.001]
  • [Cites] Ann Oncol. 2000 Jun;11(6):707-14 [10942060.001]
  • [Cites] Oncogene. 1998 Dec 24;17(25):3237-45 [9916986.001]
  • [Cites] Cell. 1996 Oct 18;87(2):171 [8861900.001]
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):416-23 [10652435.001]
  • [Cites] Nature. 1995 Aug 17;376(6541):596-9 [7637809.001]
  • [Cites] Ann Surg Oncol. 1999 Sep;6(6):604-8 [10493631.001]
  • [Cites] J Immunol Methods. 1983 Dec 16;65(1-2):55-63 [6606682.001]
  • [Cites] Cancer Res. 1996 May 15;56(10):2417-21 [8625321.001]
  • [Cites] J Biol Chem. 1999 Apr 23;274(17):11549-56 [10206961.001]
  • [Cites] Cell. 1997 Nov 14;91(4):443-6 [9390553.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4164-8 [8364909.001]
  • [Cites] Oncogene. 2000 Jul 13;19(30):3372-83 [10918594.001]
  • [Cites] Clin Chem. 1996 Jun;42(6 Pt 1):858-68 [8665676.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1821-31 [11410525.001]
  • [Cites] Cell. 1998 Sep 18;94(6):695-8 [9753316.001]
  • [Cites] Mol Cell. 1998 Jun;1(7):949-57 [9651578.001]
  • [Cites] Cancer Invest. 1996;14(1):25-53 [8597888.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Apr 21;257(3):672-7 [10208842.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1293-8 [11350897.001]
  • [Cites] Leukemia. 1997 Jul;11(7):933-9 [9204971.001]
  • [Cites] Trends Biochem Sci. 1995 May;20(5):198-202 [7610484.001]
  • [Cites] Ann Surg. 2001 May;233(5):623-9 [11323500.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4453-60 [9766678.001]
  • [Cites] J Biol Chem. 1997 Jun 27;272(26):16351-7 [9195941.001]
  • [Cites] Genes Dev. 1998 Jun 1;12(11):1551-70 [9620844.001]
  • [Cites] J Biol Chem. 2000 Mar 10;275(10):7337-42 [10702305.001]
  • [Cites] Biochem J. 1997 Aug 15;326 ( Pt 1):1-16 [9337844.001]
  • [Cites] J Interferon Cytokine Res. 2002 Jan;22(1):39-47 [11846974.001]
  • [Cites] J Natl Cancer Inst. 1996 Oct 16;88(20):1442-55 [8841019.001]
  • (PMID = 16187022.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon Regulatory Factor-1; 0 / Interferon Regulatory Factor-2; 0 / Receptors, Interferon; 77238-31-4 / Interferon-beta; EC 3.4.22.- / Caspases
  •  go-up   go-down


9. Tajanko E, Sein Anand J, Roszkowska-Kranc K, Kozłowska-Boszko B, Chodorowski Z, Korolkiewicz RP: [Drug counterfeiting--the risk to the public health]. Przegl Lek; 2007;64(4-5):357-9
Hazardous Substances Data Bank. VARDENAFIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Drug counterfeiting--the risk to the public health].
  • [Transliterated title] Podrabianie leków--zagroienie dia zdrowia publicznego.
  • Different medicines, especially erectile dysfunction drugs are involved.
  • As prescription medicines erectile dysfunction drugs should be purchased from a pharmacy only.
  • [MeSH-major] Erectile Dysfunction / drug therapy. Fraud / legislation & jurisprudence. Phosphodiesterase Inhibitors / standards. Phosphodiesterase Inhibitors / supply & distribution
  • [MeSH-minor] Carbolines / analysis. Drug Compounding. Drug Contamination / legislation & jurisprudence. Drug Contamination / statistics & numerical data. Drug Industry / legislation & jurisprudence. Drug Labeling / standards. Drug Packaging / standards. Humans. Imidazoles / analysis. Legislation, Drug / standards. Male. Piperazines / analysis. Poland. Public Health / statistics & numerical data. Purines / analysis. Quality Control. Risk Assessment / statistics & numerical data. Sildenafil Citrate. Spectrum Analysis, Raman. Sulfones / analysis. Tadalafil. Triazines / analysis. Vardenafil Dihydrochloride

  • MedlinePlus Health Information. consumer health - Erectile Dysfunction.
  • MedlinePlus Health Information. consumer health - Health Fraud.
  • Hazardous Substances Data Bank. SILDENAFIL .
  • Hazardous Substances Data Bank. TADALAFIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17724913.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Carbolines; 0 / Imidazoles; 0 / Phosphodiesterase Inhibitors; 0 / Piperazines; 0 / Purines; 0 / Sulfones; 0 / Triazines; 5O8R96XMH7 / Vardenafil Dihydrochloride; 742SXX0ICT / Tadalafil; BW9B0ZE037 / Sildenafil Citrate
  •  go-up   go-down


10. Silva MC, Santos EB, Costal EG, Filho MG, Guerreiro JF, Póvoa MM: [Clinical and laboratorial alterations in Plasmodium vivax malaria patients and glucose-6-phosphate dehydrogenase deficiency treated with primaquine at 0.50 mg/kg/day]. Rev Soc Bras Med Trop; 2004 May-Jun;37(3):215-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Alterações clínicolaboratoriais em pacientes com malária por Plasmodium vivax e deficiência de glicose-6-fosfato desidrogenase tratados com 0.50 mg/kg/dia de primaquina.
  • Clinical and laboratorial alterations indicated acute hemolysis in only the enzymopenic patients and treatment was interrupted.
  • [MeSH-major] Antimalarials / adverse effects. Glucosephosphate Dehydrogenase Deficiency / complications. Hemolysis. Malaria, Vivax / drug therapy. Primaquine / adverse effects


11. Gnekow AK, Kortmann RD, Pietsch T, Emser A: Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy -- report from the multicenter treatment study for children and adolescents with a low grade glioma -- HIT-LGG 1996 -- of the Society of Pediatric Oncology and Hematology (GPOH). Klin Padiatr; 2004 Nov-Dec;216(6):331-42
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low grade chiasmatic-hypothalamic glioma-carboplatin and vincristin chemotherapy effectively defers radiotherapy within a comprehensive treatment strategy -- report from the multicenter treatment study for children and adolescents with a low grade glioma -- HIT-LGG 1996 -- of the Society of Pediatric Oncology and Hematology (GPOH).
  • Early radiotherapy (RT) shall be deferred by chemotherapy (CT) within the concept of the HIT-LGG 1996 study, offering a comprehensive treatment strategy for all age groups.
  • Histology showed 132 pilocytic astrocytoma I degrees , 6 astrocytoma II degrees /nos and 2 DIGG/DIA I degrees (3 not known).
  • RESULTS: 82 children were treated at diagnosis, 68 upon clinical or radiological progression following observation times of 3.0 to 115.0 months.
  • At a median observation time of 50.1 months 21 tumors are stable, 3 regressive (2 not evaluable, 1 death).
  • 44/123 tumors were progressive after median 22.5 months, 37 with a chiasmatic-hypothalamic primary, 16/44 were irradiated.
  • At a median observation time of 44.7 months 2 children are in complete remission, 92 tumors are stable, 8 regressive, 9 progressive.
  • CONCLUSION: Within the comprehensive treatment strategy for low grade glioma HIT-LGG 1996 chemotherapy is effective to delay the need for early radiotherapy in chiasmatic-hypothalamic glioma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / therapy. Glioma / therapy. Hypothalamus. Optic Chiasm. Optic Nerve Neoplasms / therapy
  • [MeSH-minor] Adolescent. Age Factors. Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Carboplatin / administration & dosage. Child. Child, Preschool. Combined Modality Therapy. Data Interpretation, Statistical. Female. Follow-Up Studies. Humans. Infant. Male. Radiotherapy Dosage. Time Factors. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15565548.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


12. Pavithran K, Thomas M: Hematopoietic growth factors in drug-induced agranulocytosis. J Assoc Physicians India; 2002 May;50(5):679-81
Hazardous Substances Data Bank. DAPSONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic growth factors in drug-induced agranulocytosis.
  • Drug-induced agranulocytosis (DIA) is a potentially fatal disorder.
  • Hematopoietic growth factors have been used in the treatment of DIA.
  • We report nine cases of DIA treated with granulocyte macrophage - colony stimulating factor (GM-CSF) in a dose of 300 microg/day.
  • Mean time to reach an absolute neutrophil count of 0.5 x 10(9)/L was three days.
  • [MeSH-major] Agranulocytosis / therapy. Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Chlorpromazine / adverse effects. Dapsone / adverse effects. Dipyrone / adverse effects. Female. Humans. Male. Middle Aged. Multiple Organ Failure / etiology. Retrospective Studies. Sulfasalazine / adverse effects. Treatment Outcome

  • Hazardous Substances Data Bank. Chlorpromazine .
  • Hazardous Substances Data Bank. SULFASALAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12186123.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 3XC8GUZ6CB / Sulfasalazine; 6429L0L52Y / Dipyrone; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor; 8W5C518302 / Dapsone; U42B7VYA4P / Chlorpromazine
  •  go-up   go-down


13. Andrès E, Kurtz JE, Maloisel F: Nonchemotherapy drug-induced agranulocytosis: experience of the Strasbourg teaching hospital (1985-2000) and review of the literature. Clin Lab Haematol; 2002 Apr;24(2):99-106

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonchemotherapy drug-induced agranulocytosis: experience of the Strasbourg teaching hospital (1985-2000) and review of the literature.
  • Agranulocytosis is a life-threatening disorder that frequently occurs as an adverse reaction to drugs.
  • The overall incidence of nonchemotherapy drug-induced agranulocytosis (DIA) ranges from 2.6 to 10 cases per million patients exposed to drugs per year.
  • Although patients experiencing DIA may initially be asymptomatic, the severity of the neutropenia usually leads to severe sepsis, requiring intravenous broad-spectrum antibiotic therapy.
  • Haematopoietic growth factors have been shown to shorten the duration of neutropenia in DIA.
  • However, it has yet to be determined whether their use translates into a better outcome in DIA patients experiencing sepsis.
  • DIA still remains a rare event.
  • However, given the increased life expectancy and subsequent longer exposure to drugs, as well as the development of new agents, physicians should be aware of this complication and its management.
  • [MeSH-minor] Aged. Anti-Bacterial Agents / adverse effects. Anti-Bacterial Agents / therapeutic use. Antithyroid Agents / adverse effects. Case-Control Studies. Cohort Studies. Disease Susceptibility. Female. France / epidemiology. Granulocyte Colony-Stimulating Factor / therapeutic use. Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use. Humans. Incidence. Infection / drug therapy. Infection / etiology. Infection / mortality. Male. Middle Aged. Platelet Aggregation Inhibitors / therapeutic use. Randomized Controlled Trials as Topic. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11985555.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antithyroid Agents; 0 / Platelet Aggregation Inhibitors; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  • [Number-of-references] 43
  •  go-up   go-down


14. Lake Y, Pinnock S: Improved patient acceptability with a transdermal drug-in-adhesive oestradiol patch. Aust N Z J Obstet Gynaecol; 2000 Aug;40(3):313-6
Hazardous Substances Data Bank. ESTRADIOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved patient acceptability with a transdermal drug-in-adhesive oestradiol patch.
  • The aim of this trial was to assess the relative patient acceptability of two transdermal oestradiol patches used in treatment of oestrogen deficiency in postmenopausal women.
  • Thirty-five hysterectomised postmenopausal women with no previous experience of transdermal oestradiol delivery systems received treatment with either once-weekly drug-in-adhesive (DIA) patches or twice-weekly reservoir patches for 4 weeks, and were then switched to the alternative treatment for a further 4 weeks.
  • At the end of the study, the patients completed a questionnaire to assess their relative preference for a number of characteristics of the 2 transdermal systems and, where possible, their preference for transdermal compared with oral hormone replacement therapy.
  • Thirty-one patients completed the study; four withdrew during treatment with the reservoir patch.
  • The DIA patch was preferred for being 'easiest to remember to apply' by 80% of patients (p < 0.01), 'easiest to open' and 'easiest to apply' by 68% (p = 0.025), and as having 'best cosmetic appearance' by 65% (p = 0.05) and 'best overall skin adhesion' by 61% (p < 0.01).
  • The DIA patch was selected by 87% of patients as their preferred treatment overall (p = 0.001).
  • Ninety-one per cent of 22 responding patients were at least as confident of treatment with transdermal patches as with oral hormone replacement therapy (p = 0.006) and 74 % of 27 responders preferred transdermal to oral treatment (p = 0.004).
  • The DIA patch appears to be more acceptable to patients than the reservoir patch as a transdermal oestradiol delivery system for the treatment of postmenopausal oestrogen deficiency.
  • Characteristics of the DIA patch which may account for improved patient acceptance include ease of remembering once-weekly patch application, improved cosmetic appearance and comfort, and better adhesion.
  • [MeSH-major] Drug Delivery Systems. Estradiol / administration & dosage. Estrogen Replacement Therapy / methods. Patient Acceptance of Health Care
  • [MeSH-minor] Administration, Cutaneous. Adult. Aged. Delayed-Action Preparations. Drug Administration Schedule. Female. Humans. Hysterectomy. Middle Aged. New Zealand. Patient Compliance. Patient Satisfaction. Postmenopause. Probability

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11065040.001).
  • [ISSN] 0004-8666
  • [Journal-full-title] The Australian & New Zealand journal of obstetrics & gynaecology
  • [ISO-abbreviation] Aust N Z J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] AUSTRALIA
  • [Chemical-registry-number] 0 / Delayed-Action Preparations; 4TI98Z838E / Estradiol
  •  go-up   go-down


15. Hwa SY, Burkhardt D, Little C, Ghosh P: The effects of orally administered diacerein on cartilage and subchondral bone in an ovine model of osteoarthritis. J Rheumatol; 2001 Apr;28(4):825-34
MedlinePlus Health Information. consumer health - Osteoarthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: An ovine model of osteoarthritis (OA) induced by bilateral lateral meniscectomy (BLM) was used to evaluate in vivo effects of the slow acting antiarthritic drug diacerein (DIA) on degenerative changes in cartilage and subchondral bone of the operated joints.
  • Half of the BLM group (n = 10) were given DIA (25 mg/kg orally) daily for 3 mo, then 50 mg/kg daily for a further 6 mo.
  • Five DIA, 5 MEN, and 5 NOC animals were sacrificed at 3 mo and the remainder at 9 mo postsurgery.
  • RESULTS: No significant difference was observed in the modified Mankin scores for cartilage from the DIA and MEN groups at 3 or 9 mo.
  • However, in animals treated with DIA, the thickness of cartilage (p = 0.05) and subchondral bone (p = 0.05) in the lesion (middle) zone of the lateral tibial plateau were decreased relative to the corresponding zone of the MEN group at 3 mo (p = 0.05).
  • In contrast, the subchondral bone thickness of the outer zone of lateral tibial plateau and lateral femoral condyle of both MEN and DIA groups increased after 9 mo, while BMD remained the same as in the NOC.
  • CONCLUSION: DIA treatment of meniscectomized animals mediated selective responses of cartilage and subchondral bone to the altered mechanical stresses induced across the joints by this procedure.
  • While subchondral bone thickness in tibial lesion sites was reduced, cartilage and bone proliferation at the outer joint margins, a region where osteophyte formation occurred, were enhanced, suggesting that DIA supported the processes of repair and endochondral ossification.
  • [MeSH-major] Anthraquinones / therapeutic use. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Bone and Bones / drug effects. Cartilage, Articular / drug effects. Osteoarthritis / drug therapy. Osteoarthritis / pathology
  • [MeSH-minor] Administration, Oral. Animals. Bone Density / drug effects. Female. Sheep

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11327258.001).
  • [ISSN] 0315-162X
  • [Journal-full-title] The Journal of rheumatology
  • [ISO-abbreviation] J. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Anthraquinones; 0 / Anti-Inflammatory Agents, Non-Steroidal; 4HU6J11EL5 / diacetylrhein
  •  go-up   go-down


16. Kato A, Yamashita Y, Nakagawa S, Koike Y, Adachi I, Hollinshead J, Nash RJ, Ikeda K, Asano N: 2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease. Bioorg Med Chem; 2010 Jun 1;18(11):3790-4
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease.
  • The structures of new iminosugars were elucidated by spectroscopic methods as 2,5-dideoxy-2,5-imino-d-altritol (DIA) (2), beta-1-C-butenyl-1-deoxygalactonojirimycin (8), 2,3-dideoxy-beta-1-C-ethyl-1-deoxygalactonojirimycin (9), and 6-O-beta-d-glucopyranosyl-2,3-dideoxy-beta-1-C-ethyl-1-deoxygalactonojirimycin (10).
  • The present work elucidated that DIA was a powerful competitive inhibitor of human lysosome alpha-galactosidase A (alpha-Gal A) with a K(i) value of 0.5muM.
  • Furthermore, DIA improved the thermostability of alpha-Gal A in vitro and increased intracellular alpha-Gal A activity by 9.6-fold in Fabry R301Q lymphoblasts after incubation for 3days.
  • These experimental results suggested that DIA would act as a specific pharmacological chaperone to promote the smooth escape from the endoplasmic reticulum (ER) quality control system and to accelerate transport and maturation of the mutant enzyme.
  • [MeSH-major] Fabry Disease / drug therapy. Molecular Chaperones / chemistry. Phytotherapy / methods. Sugar Alcohols / therapeutic use

  • Genetic Alliance. consumer health - BabysFirstTest - Fabry Disease.
  • Genetic Alliance. consumer health - Fabry Disease.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • BindingDB. BindingDB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20457528.001).
  • [ISSN] 1464-3391
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Imino Sugars; 0 / Molecular Chaperones; 0 / Mutant Proteins; 0 / Piperidines; 0 / Plant Extracts; 0 / Pyrrolidines; 0 / Sugar Alcohols; 5552-13-6 / altritol; EC 3.2.1.22 / alpha-Galactosidase
  •  go-up   go-down


17. Kim SH, Na S, Choi JS, Na SH, Shin S, Koh SO: An evaluation of diaphragmatic movement by M-mode sonography as a predictor of pulmonary dysfunction after upper abdominal surgery. Anesth Analg; 2010 May 1;110(5):1349-54
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we evaluated whether diaphragmatic inspiratory amplitude (DIA) as measured by M-mode sonography can be a predictor of pulmonary dysfunction.
  • We measured the DIA (cm) during quiet, deep, and sniff breathing.
  • RESULTS: After liver lobectomy, DIA during deep breathing and vital capacity (VC) showed significant reductions of 60% from their preoperative values on PODs 1 and 2 (P < 0.001).
  • During deep breathing, DIA showed a significant correlation with VC (r = 0.839, P < 0.0001).
  • The best cutoff values of DIA for detecting 30% and 50% decreases of VC from preoperative values, calculated by receiver operating characteristic analysis, were 3.61 and 2.41 cm, with sensitivity of 94% and 81% and specificity of 76% and 91%, respectively (P = 0.0001).
  • CONCLUSIONS: DIA using M-mode sonography showed a linear correlation with VC measured by spirometry throughout the postoperative period.
  • [MeSH-minor] Adolescent. Adult. Aged. Analgesia, Patient-Controlled. Anesthesia, General. Digestive System Surgical Procedures. Female. Humans. Liver / surgery. Male. Middle Aged. Pain Measurement. Pain, Postoperative / diagnosis. Pain, Postoperative / drug therapy. Predictive Value of Tests. Prognosis. Prospective Studies. ROC Curve. Respiratory Function Tests. Respiratory Paralysis / etiology. Spirometry. Vital Capacity / physiology. Young Adult

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20418298.001).
  • [ISSN] 1526-7598
  • [Journal-full-title] Anesthesia and analgesia
  • [ISO-abbreviation] Anesth. Analg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


18. Park HY, Lee NY, Kim JH, Park CK: Intraocular pressure lowering, change of antiapoptotic molecule expression, and neuroretinal changes by dorzolamide 2%/timolol 0.5% combination in a chronic ocular hypertension rat model. J Ocul Pharmacol Ther; 2008 Dec;24(6):563-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Retinal ganglion cell (RGC) retrograde labeling and quantification with 4-di-10-ASP (DiA) and expression of glial fibrillary acidic protein (GFAP) were detected before and after the administration of dorzolamide 2%/timolol 0.5%.
  • Treatment of ocular hypertensive eyes with dorzolamide 2%/timolol 0.5% significantly reduced, intraocular pressure when compared to the control eyes.
  • Labeling of RGCs with DiA showed a significant decrease in RGC loss after the administration of dorzolamide 2%/timolol 0.5%.
  • [MeSH-major] Intraocular Pressure / drug effects. Ocular Hypertension / drug therapy. Proto-Oncogene Proteins c-bcl-2 / genetics. Retinal Ganglion Cells / drug effects. Sulfonamides / administration & dosage. Thiophenes / administration & dosage. Timolol / administration & dosage. bcl-X Protein / genetics
  • [MeSH-minor] Animals. Cell Survival / drug effects. Disease Models, Animal. Drug Combinations. Glial Fibrillary Acidic Protein / analysis. Male. RNA, Messenger / analysis. Rats. Rats, Sprague-Dawley

  • Hazardous Substances Data Bank. TIMOLOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19049297.001).
  • [ISSN] 1557-7732
  • [Journal-full-title] Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics
  • [ISO-abbreviation] J Ocul Pharmacol Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Glial Fibrillary Acidic Protein; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / Sulfonamides; 0 / Thiophenes; 0 / bcl-X Protein; 817W3C6175 / Timolol; 9JDX055TW1 / dorzolamide
  •  go-up   go-down


19. An J, Camara AK, Chen Q, Stowe DF: Effect of low [CaCl2] and high [MgCl2] cardioplegia and moderate hypothermic ischemia on myoplasmic [Ca2+] and cardiac function in intact hearts. Eur J Cardiothorac Surg; 2003 Dec;24(6):974-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We reported previously that CP decreased the rise in cardiac diastolic (dia) [Ca(2+)](i) observed during 4 h cold storage at 3 degrees C in Krebs-Ringer's (KR) solution and decreased dia[Ca(2+)](i) and increased systolic (sys) [Ca(2+)](i) and function on reperfusion after cold storage.
  • METHODS: We compared effects of 4.5 mM K(+)(o), 2.5 mM Ca(2+)(o) and 2.4 mM Mg(2+)(o) KR solution with a higher K(+)(o) (18 mM), a lower Ca(2+)(o) (1.25 mM) and/or higher Mg(2+)(o) (7.2 mM) CP solutions on cardiac mechanic function and sys and dia[Ca(2+)](i) during and after moderate hypothermic global ischemia (17 degrees C for 4 h) in guinea pig intact hearts isolated by the Langendorff technique.
  • Isovolumetric left ventricular pressure (LVP) was measured with a transducer connected to a fluid-filled balloon placed in the LV and [Ca(2+)](i) was measured using indo-1 fluorescence and a fiberoptic cable placed on the LV free wall.
  • RESULTS: For all CP groups compared to the KR control group after 60 min reperfusion, we observed significant lowering of dia[Ca(2+)](i) by 47%, left ventricular diastolic pressure (diaLVP) by 55%, and infarct size by 43%.
  • We also found significant elevation of sys[Ca(2+)](i) by 25%, d[Ca(2+)](i)/dt(max) and d[Ca(2+)](i)/dt(min) by 33 and 34%, sys-diaLVP by 55%, dLVP/dt(max) and dLVP/dt(min) by 34 and 40%, coronary flow by 31%, cardiac efficiency by 21%, and MVO(2) by 25%.
  • [MeSH-major] Calcium Chloride / pharmacology. Cardioplegic Solutions / pharmacology. Heart / drug effects. Heart Arrest, Induced / methods. Magnesium Chloride / pharmacology
  • [MeSH-minor] Animals. Calcium / metabolism. Guinea Pigs. Myocardial Reperfusion Injury / pathology. Myocardial Reperfusion Injury / prevention & control. Myocardium / metabolism. Organ Culture Techniques. Potassium / pharmacology. Ventricular Function, Left / drug effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM CHLORIDE .
  • Hazardous Substances Data Bank. POTASSIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. MAGNESIUM CHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14643817.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Grant] United States / PHS HHS / / 058691
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cardioplegic Solutions; 02F3473H9O / Magnesium Chloride; M4I0D6VV5M / Calcium Chloride; RWP5GA015D / Potassium; SY7Q814VUP / Calcium
  •  go-up   go-down


20. Varadarajan SG, An J, Novalija E, Smart SC, Stowe DF: Changes in [Na(+)](i), compartmental [Ca(2+)], and NADH with dysfunction after global ischemia in intact hearts. Am J Physiol Heart Circ Physiol; 2001 Jan;280(1):H280-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Langendorff-prepared guinea pig hearts were crystalloid perfused, and the left ventricular (LV) pressure (LVP), first derivative of LVP (LV dP/dt), coronary flow, and O(2) extraction and consumption were measured before, during, and after 30-min global ischemia and 60-min reperfusion.
  • Ca(2+), Na(+), and NADH were measured by luminescence spectrophotometry at the LV free wall using indo 1 and sodium benzofuran isophthalate, respectively, after subtracting changes in tissue autofluorescence (NADH).
  • Mechanical responses to changes in cytosolic-systolic (subscript sys), diastolic (subscript dia), and mitochondrial Ca(2+) were tested over a range of extracellular [Ca(2+)] before and after ischemia-reperfusion.
  • Both [Ca(2+)](sys) and [Ca(2+)](dia) doubled at 1-min reperfusion but returned to preischemia values within 10 min, whereas [Ca(2+)](mito) was elevated over 60-min reperfusion.
  • Reperfusion dissociated [Ca(2+)](dia) and [Ca(2+)](sys) from contractile function as LVP(sys-dia) and the rise in LV dP/dt (LV dP/dt(max)) were depressed by one-third and the fall in LV dP/dt (LV dP/dt(min)) was depressed by one-half at 30-min reperfusion, whereas LVP(dia) remained markedly elevated.
  • [Ca(2+)](sys-dia) sensitivity at 100% LV dP/dt(max) was not altered after reperfusion, but [Ca(2+)](dia) at 100% LV dP/dt(min) and [Ca(2+)](mito) at 100% LV dP/dt(max) were markedly shifted right on reperfusion (ED(50) +36 and +125 nM [Ca(2+)], respectively) with no change in slope.

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11123243.001).
  • [ISSN] 0363-6135
  • [Journal-full-title] American journal of physiology. Heart and circulatory physiology
  • [ISO-abbreviation] Am. J. Physiol. Heart Circ. Physiol.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / R01-HLBI-58691; United States / NIGMS NIH HHS / GM / R01-T32 GM-08377
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorescent Dyes; 0 / Indoles; 0 / Sodium Channels; 0U46U6E8UK / NAD; N18RMK75W1 / indo-1; SY7Q814VUP / Calcium
  •  go-up   go-down


21. De Luca A, Pierno S, Liantonio A, Cetrone M, Camerino C, Fraysse B, Mirabella M, Servidei S, Rüegg UT, Conte Camerino D: Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. J Pharmacol Exp Ther; 2003 Jan;304(1):453-63
Hazardous Substances Data Bank. CREATINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A preclinical screening for prompt-to-use drugs that are safer than steroids and beneficial in Duchenne muscular dystrophy was performed.
  • The exercise produced a significant weakness and an impairment of gCl, by further decreasing the already low value of degenerating diaphragm (DIA) and fully hampering the increase of gCl typical of regenerating extensor digitorum longus (EDL) mdx muscle.
  • The amelioration of gCl was drug- and muscle-specific: taurine was effective in EDL, but not in DIA muscle; IGF-1 and PDN were fully restorative in both muscles, whereas creatine was ineffective.
  • [MeSH-major] Insulin-Like Growth Factor I / therapeutic use. Muscular Dystrophy, Animal / therapy. Physical Conditioning, Animal / physiology. Taurine / therapeutic use
  • [MeSH-minor] Animals. Creatine / therapeutic use. Disease Progression. Electrophysiology. Ion Channels / metabolism. Male. Mice. Mice, Inbred C57BL. Mice, Inbred mdx. Muscle Contraction / physiology. Muscle Fibers, Skeletal / drug effects. Muscle Fibers, Skeletal / pathology. Muscle Fibers, Skeletal / physiology. Muscle, Skeletal / drug effects. Muscle, Skeletal / pathology. Muscle, Skeletal / physiology. Patch-Clamp Techniques

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Taurine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12490622.001).
  • [ISSN] 0022-3565
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ion Channels; 1EQV5MLY3D / Taurine; 67763-96-6 / Insulin-Like Growth Factor I; MU72812GK0 / Creatine
  •  go-up   go-down


22. Park KH, Song HC, Na K, Bom HS, Lee KH, Kim S, Kang D, Lee DH: Ionic strength-sensitive pullulan acetate nanoparticles (PAN) for intratumoral administration of radioisotope: ionic strength-dependent aggregation behavior and (99m)Technetium retention property. Colloids Surf B Biointerfaces; 2007 Sep 1;59(1):16-23
Hazardous Substances Data Bank. TECHNETIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With increases in the IS of the dialysis media (IS(dia)), the CAC of PAN was reduced gradually and the rigidity of the hydrophobic core in PAN was increased.
  • The stabilities of PANs prepared from various IS(dia) were also monitored with changes in the turbidity and particle size in different IS solutions.
  • In the case of PAN prepared at an IS(dia)=0.0, the turbidity was dramatically reduced with increasing IS due to the facilitation of aggregation between the particles, whereas in the other cases, these changes were negligible.
  • [MeSH-minor] Acetylation. Animals. Carbohydrate Sequence. Cell Line, Tumor. Drug Carriers / administration & dosage. Drug Carriers / chemistry. Male. Mice. Mice, Inbred BALB C. Microscopy, Electron, Scanning. Molecular Sequence Data. Molecular Structure. Neoplasms, Experimental / radiotherapy. Osmolar Concentration. Particle Size. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17532195.001).
  • [ISSN] 0927-7765
  • [Journal-full-title] Colloids and surfaces. B, Biointerfaces
  • [ISO-abbreviation] Colloids Surf B Biointerfaces
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Glucans; 0 / Radiopharmaceuticals; 7440-26-8 / Technetium; 8ZQ0AYU1TT / pullulan
  •  go-up   go-down


23. Rao NV, Pujar B, Nimbal SK, Shantakumar SM, Satyanarayana S: Nootropic activity of tuber extract of Pueraria tuberosa (Roxb). Indian J Exp Biol; 2008 Aug;46(8):591-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nootropic effect of alcoholic (ALE; 50, 75, 100 mg/kg) and aqueous (AQE; 100, 200, 400 mg/kg) extracts of P. tuberosa was evaluated by using Elevated Plus Maze (EPM), scopolamine-induced amnesia (SIA), diazepam-induced amnesia (DIA), clonidine-induced (NA-mediated) hypothermia (CIH), lithium-induced (5-HT mediated) head twitches (LIH) and haloperidol-induced (DA- mediated) catalepsy (HIC) models.
  • Piracetam was used as the standard drug.
  • A significant increase in inflexion ratio (IR) was recorded in EPM, SIA and DIA models.
  • [MeSH-minor] Amnesia / drug therapy. Animals. Catalepsy / drug therapy. Disease Models, Animal. Female. Hypothermia / drug therapy. Learning / drug effects. Male. Memory / drug effects. Mice. Rats

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18814488.001).
  • [ISSN] 0019-5189
  • [Journal-full-title] Indian journal of experimental biology
  • [ISO-abbreviation] Indian J. Exp. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Nootropic Agents; 0 / Plant Extracts
  •  go-up   go-down


24. Andrès E, Kurtz JE, Perrin AE, Dufour P, Schlienger JL, Maloisel F: Haematopoietic growth factor in antithyroid-drug-induced agranulocytosis. QJM; 2001 Aug;94(8):423-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Haematopoietic growth factor in antithyroid-drug-induced agranulocytosis.
  • Drug-induced agranulocytosis (DIA) is often caused by antithyroid drugs.
  • We retrospectively studied the use of granulocyte colony-stimulating factor (G-CSF) therapy in antithyroid-DIA.
  • Data for 20 patients (10 treated with G-CSF) with antithyroid-DIA (neutrophil count <0.5x10(9)/l) were extracted from a cohort study of DIA patients (n=110).
  • Carbimazole (n=19) and benzylthiouracile (n=1) were the causative drugs, at mean doses of 30 mg/day (range 20-60) and 100 mg/day (range 50-150), respectively, for a mean of 37 days (range 31-90).
  • Antithyroid drugs were prescribed for Graves' disease (n=8), thyrotoxicosis related to amiodarone intake (n=6) and multinodular goitre (n=6).
  • Mean durations of haematological recovery, antibiotic therapy and hospitalization were significantly reduced with G-CSF: 6.8+/-4 days vs. 11.6+/-5; 7.5+/-3.8 days vs. 12+/-4.5; and 7.3+/-4.8 days vs. 13+/-6.1, respectively (all p<0.05).
  • [MeSH-major] Agranulocytosis / drug therapy. Antithyroid Agents / adverse effects. Granulocyte Colony-Stimulating Factor / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cost-Benefit Analysis. Female. Health Care Costs. Humans. Length of Stay. Leukocyte Count. Male. Middle Aged. Neutrophils. Prognosis. Retrospective Studies. Statistics, Nonparametric. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11493719.001).
  • [ISSN] 1460-2725
  • [Journal-full-title] QJM : monthly journal of the Association of Physicians
  • [ISO-abbreviation] QJM
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antithyroid Agents; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  •  go-up   go-down


25. Akhtar N, Junaid A, Khalid A, Ahmed W, Shah MA, Rahman H: Report: frequency of aspirin resistance in patients with coronory artery disease in Pakistan. Pak J Pharm Sci; 2009 Apr;22(2):230-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Details were entered on a pre-designed questionnaire and aspirin response assay was performed on IMPACT-R (Dia Med AG 1785 Cressier Morat, Switzerland).
  • 73.2% of study population were male and 26.8% were female, with a mean age of 57.2 years.
  • [MeSH-major] Aspirin / therapeutic use. Coronary Artery Disease / drug therapy. Drug Resistance. Platelet Aggregation / drug effects. Platelet Aggregation Inhibitors / therapeutic use


26. Winkler I, Blotnik S, Shimshoni J, Yagen B, Devor M, Bialer M: Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain. Br J Pharmacol; 2005 Sep;146(2):198-208
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Antiepileptic drugs (AEDs) are often utilized in the treatment of neuropathic pain.
  • We synthesized VPA's corresponding amide: valpromide (VPD), two of VPAs isomers and their corresponding amides; valnoctic acid (VCA), valnoctamide (VCD), diisopropyl acetic acid (DIA), diisopropylacetamide (DID), and VPD's congener: N-methyl-VPD (MVPD).
  • The antiallodynic effect of VPA, VPD, VCD and DID was obtained at plasma concentrations of 125, 24, 18 and 7 mg l(- 1), respectively, with a good pharmacokinetic-pharmacodynamic correlation and a minimal lag response.
  • VCD and DID were found to have minimal motor and sedative side effects at analgesic doses, and were equipotent to GBP, currently the leading drug in neuropathic pain treatment.
  • Consequently, VCD and DID have potential to become new drugs for the treatment of neuropathic pain.
  • [MeSH-major] Analgesics. Anticonvulsants / pharmacology. Pain / drug therapy. Pain / etiology. Peripheral Nervous System Diseases / complications. Valproic Acid / analogs & derivatives
  • [MeSH-minor] Animals. Hyperalgesia / drug therapy. Isomerism. Ligation. Male. Pain Measurement / drug effects. Physical Stimulation. Postural Balance / drug effects. Psychomotor Performance / drug effects. Rats. Rats, Sprague-Dawley. Sensory Thresholds / drug effects. Spinal Nerves / injuries. Spinal Nerves / pathology. Structure-Activity Relationship


27. Blume A, Mergl R, Niedermeier N, Kunz J, Pfeiffer-Gerschel T, Karch S, Havers I, Hegerl U: [Evaluation of an online discussion forum for depressive patients and their relatives--an examination focussing motives and effects of participation]. Neuropsychiatr; 2009;23(1):42-51
MedlinePlus Health Information. consumer health - Caregivers.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The question of which diagnoses are predominant among the forum members and the question of their treatment status shall be answered.
  • METHODS: 55 active users were interviewed by telephone using a computer-assisted version of a fully structured psychiatric interview (DIA-X) and online with the Beck Depression Inventory (BDI).
  • Moreover, their treatment status and their motivation to use the online forum were asked for.
  • 90.2% received outpatient treatment before, 64.7% inpatient treatment.
  • The respondents stated that their trust in medical treatment was raised (63.3%) and that they were encouraged to seek professional help (61.2%).
  • Furthermore, 32.7% of the interviewed participants rated their attitudes towards the treatment with medication more positive than before being a member in the discussion forum.
  • [MeSH-minor] Adult. Aged. Antidepressive Agents / therapeutic use. Comorbidity. Female. Germany. Humans. Interviews as Topic. Male. Middle Aged. Patient Care Team. Patient Satisfaction. Personality Assessment. Phobic Disorders / diagnosis. Phobic Disorders / epidemiology. Phobic Disorders / therapy. Psychotherapy. Somatoform Disorders / diagnosis. Somatoform Disorders / epidemiology. Somatoform Disorders / therapy. Therapy, Computer-Assisted

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19272291.001).
  • [ISSN] 0948-6259
  • [Journal-full-title] Neuropsychiatrie : Klinik, Diagnostik, Therapie und Rehabilitation : Organ der Gesellschaft Österreichischer Nervenärzte und Psychiater
  • [ISO-abbreviation] Neuropsychiatr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antidepressive Agents
  •  go-up   go-down


28. Mori T, Eguchi Y, Shimizu T, Endo Y, Yoshioka T, Hanasawa K, Tani T: A case of acute hepatic insufficiency treated with novel plasmapheresis plasma diafiltration for bridge use until liver transplantation. Ther Apher; 2002 Dec;6(6):463-6
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A patient with acute hepatic insufficiency induced by a drug presented to our institution, and we performed a novel plasmapheresis that we call plasma dia-filtration (PDF).
  • She underwent 11 sessions of PDF for a duration of about 9 h for each procedure using the Evacure EC-2A filter together with 20 units of fresh frozen plasma and dialysate simultaneously.
  • Serum levels of total bilirubin and prothrombin time were significantly improved after she underwent each procedure.
  • However, after the third procedure the levels returned to the same level as on the previous day.
  • Encephalopathy improved after the first procedure, and this improvement was maintained until the ninth procedure.
  • The patient prepared to undergo liver transplantation after the tenth procedure because of the development of hepatic coma, but she died of respiratory insufficiency before undergoing the procedure.
  • Accordingly in this case, PDF worked to maintain liver function in acute liver failure and may act as bridge therapy until the patient can undergo liver transplantation.
  • [MeSH-major] Hemodiafiltration. Liver Failure, Acute / therapy. Plasmapheresis
  • [MeSH-minor] Adult. Bilirubin / blood. Blood Proteins / analysis. Female. Hepatic Encephalopathy / chemically induced. Hepatic Encephalopathy / therapy. Humans. Prothrombin Time

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12460412.001).
  • [ISSN] 1091-6660
  • [Journal-full-title] Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis
  • [ISO-abbreviation] Ther Apher
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Proteins; RFM9X3LJ49 / Bilirubin
  •  go-up   go-down


29. Elias D, Avron A, Tamir M, Raz I: DiaPep277 preserves endogenous insulin production by immunomodulation in type 1 diabetes. Ann N Y Acad Sci; 2006 Oct;1079:340-4
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DiaPep277 preserves endogenous insulin production by immunomodulation in type 1 diabetes.
  • DiaPep277 is an immunomodulatory peptide that arrests beta cell destruction in mouse models of type 1 diabetes mellitus (T1DM).
  • After 13 months, 1.0 mg Dia Pep277 treatment significantly (P = 0.02) preserved beta cell function as compared to the control with a trend for reduced HbA1c.
  • [MeSH-major] Diabetes Mellitus, Type 1 / drug therapy. Hypoglycemic Agents / metabolism. Insulin / biosynthesis. Peptide Fragments / therapeutic use. Peptides / therapeutic use
  • [MeSH-minor] Amino Acid Sequence. Area Under Curve. C-Peptide / blood. Chaperonin 60. Female. Follow-Up Studies. Hemoglobin A, Glycosylated / analysis. Humans. Insulin-Secreting Cells / metabolism. Male. Molecular Sequence Data. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17130576.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / C-Peptide; 0 / Chaperonin 60; 0 / DiaPep 277; 0 / Hemoglobin A, Glycosylated; 0 / Hypoglycemic Agents; 0 / Insulin; 0 / Peptide Fragments; 0 / Peptides
  •  go-up   go-down


30. Bresnihan B, Pontifex E, Thurlings RM, Vinkenoog M, El-Gabalawy H, Fearon U, Fitzgerald O, Gerlag DM, Rooney T, van de Sande MG, Veale D, Vos K, Tak PP: Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers. J Rheumatol; 2009 Aug;36(8):1800-2
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers.
  • METHODS: Synovial biopsies obtained at arthroscopy from patients with rheumatoid arthritis before and 160 days after rituximab therapy were selected and coded.
  • Digital image analysis (DIA) was employed at both centers to quantify sublining CD68 expression.
  • Similarly, the intracenter correlations for DeltaCD68sl expression after treatment were R = 0.998, p = 0.000, for sections stained at AMC and R = 0.880, p = 0.000, for sections stained at SVUH.
  • Examination of serial biopsy samples can be used reliably to screen for interesting biological effects at the site of inflammation at an early stage of drug development.
  • [MeSH-major] Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Arthritis, Rheumatoid / drug therapy. Biomarkers / metabolism. Clinical Trials as Topic / methods. Clinical Trials as Topic / standards
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antirheumatic Agents / therapeutic use. Biopsy. Drug Monitoring / methods. Drug Monitoring / standards. Humans. Macrophages / pathology. Reproducibility of Results. Rituximab. Synovial Membrane / metabolism. Synovial Membrane / pathology

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Clinical Trials.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19671815.001).
  • [ISSN] 0315-162X
  • [Journal-full-title] The Journal of rheumatology
  • [ISO-abbreviation] J. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Validation Studies
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antirheumatic Agents; 0 / Biomarkers; 0 / CD68 antigen, human; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


31. Sadiq S, Nagi AH, Shahzad M, Zia A: The reno-protective effect of aqueous extract of Carum carvi (black zeera) seeds in streptozotocin induced diabetic nephropathy in rodents. Saudi J Kidney Dis Transpl; 2010 Nov;21(6):1058-65
Hazardous Substances Data Bank. UREA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Blood samples were collected on the 60 th day, and kidneys were also extracted for examination.
  • In conclusion, high dose of Carum carvi aqueous seeds extract (60 mg/kg) showed reno-protection against STZ induced dia-betic nephropathy in rats.
  • [MeSH-major] Carum. Diabetes Mellitus, Experimental / drug therapy. Diabetic Nephropathies / prevention & control. Kidney / drug effects. Plant Extracts / pharmacology. Protective Agents / pharmacology
  • [MeSH-minor] Animals. Biomarkers / blood. Blood Glucose / metabolism. Body Weight / drug effects. Creatinine / blood. Male. Proteinuria / etiology. Proteinuria / prevention & control. Rats. Rats, Wistar. Seeds. Urea / blood. Urination / drug effects

  • MedlinePlus Health Information. consumer health - Diabetic Kidney Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21060174.001).
  • [ISSN] 1319-2442
  • [Journal-full-title] Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia
  • [ISO-abbreviation] Saudi J Kidney Dis Transpl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Blood Glucose; 0 / Plant Extracts; 0 / Protective Agents; 8W8T17847W / Urea; AYI8EX34EU / Creatinine
  •  go-up   go-down


32. Magalhães MS, Fechine FV, Macedo RN, Monteiro DL, Oliveira CC, Brito GA, Moraes ME, Moraes MO: Effect of a combination of medium chain triglycerides, linoleic acid, soy lecithin and vitamins A and E on wound healing in rats. Acta Cir Bras; 2008 May-Jun;23(3):262-9
Hazardous Substances Data Bank. VITAMIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of a combination of medium chain triglycerides, linoleic acid, soy lecithin and vitamins A and E on wound healing in rats.
  • PURPOSE: The aim of the study was to determine the effect of a combination of medium chain triglycerides (caprylic, capric, caproic and lauric acids), linoleic acid (essential fatty acid), vitamins A and E and soy lecithin, through a morphometric study, on the wound healing kinetics of experimental cutaneous ulcers.
  • Based on the wound area, we determined the degree of tissue repair and mean rate of repair at different time intervals.
  • The overall mean rate of repair was equally similar at 12 days of treatment: 25.79 mm2/dia in the Control group, 25.42 mm2/dia in the Reference group and 27.38 mm2/dia in the Test group.
  • CONCLUSION: The test preparation, applied topically on the experimentally induced cutaneous ulcers in rats, did not accelerate the process of tissue repair by secondary union.

  • MedlinePlus Health Information. consumer health - Vitamins.
  • Hazardous Substances Data Bank. LINOLEIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18552998.001).
  • [ISSN] 0102-8650
  • [Journal-full-title] Acta cirurgica brasileira
  • [ISO-abbreviation] Acta Cir Bras
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Soybean Proteins; 0 / Triglycerides; 0 / Vitamins; 11103-57-4 / Vitamin A; 1406-18-4 / Vitamin E; 9KJL21T0QJ / Linoleic Acid
  •  go-up   go-down


33. Barnay C, Taieb J, Morice R, Jouve B, Rahal Y, Benchaa T, Alfares A, Lenaers C, Boulain L, Pizigo E: [Acquired long QT syndrome: a dominant problem?]. Ann Cardiol Angeiol (Paris); 2006 Nov;55(6):321-7
Hazardous Substances Data Bank. MAGNESIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • QT prolongation is essentially of pharmacologic origin.
  • The term "repolarisation reserve" expresses the variable risk of arrhythmia among individuals under the same drug blocking Ikr.
  • Acquired dia, electrolytic disorders, cardiac disease, neurologic disorders, nutrition troubles, female gender) can play a role as well as the metabolic processing of pharmacological agents by Cytochrome P450 and various inhibitors or inductors of this system which can influence the half life of drugs.
  • The list of drugs involved is continuously increasing: antiarrhythmics, antihistamines, psychotropics, anti-infectious are the main categories involved.
  • Risk prediction is difficult particularly for non cardiovascular drugs and a low risk incidence.
  • An other risk is to exclude patients from the benefit of an efficient drug for a serious but not frequent risk, at last an industrial risk for the manufacturer when a drug is withdrawn lately when important quantities of money have already been invested for its development.
  • The treatment of the arrhythmias is based on heart rate acceleration by Isoprenaline or intravenous pacing and on intravenous administration of magnesium.
  • [MeSH-minor] Adrenergic beta-Agonists / therapeutic use. Drug Therapy, Combination. Electric Countershock. Humans. Isoproterenol / therapeutic use. Magnesium / administration & dosage. Magnesium / therapeutic use. Risk Factors

  • Genetic Alliance. consumer health - Long QT Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17191590.001).
  • [ISSN] 0003-3928
  • [Journal-full-title] Annales de cardiologie et d'angéiologie
  • [ISO-abbreviation] Ann Cardiol Angeiol (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adrenergic beta-Agonists; I38ZP9992A / Magnesium; L628TT009W / Isoproterenol
  • [Number-of-references] 16
  •  go-up   go-down


34. Kim SH, Chung WY, Zo JH, Kim MA, Chang HJ, Cho YS, Youn TJ, Chae IH, Choi DJ, Gwak JJ, Lee HY, Park JS, Kang HJ, Kim YJ, Kim HS: Efficacy and tolerability of two formulations of ramipril in Korean adults with mild to moderate essential hypertension: an 8-week, multicenter, prospective, randomized, open-label, parallel-group noninferiority trial. Clin Ther; 2009 May;31(5):988-98
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: This study was designed to compare the efficacy and tolerability of a new generic formulation of ramipril (test) and the branded formulation of ramipril (reference) to satisfy regulatory requirements for marketing of the generic product for use in Korean patients with mild to moderate hypertension.
  • METHODS: This was an 8-week, multicenter, prospective, randomized, open-label, parallel-group non-inferiority trial in adult patients (age > 18 years) with mild to moderate essential hypertension (sitting dia-stolic blood pressure [SiDBP] 90-109 mm Hg).
  • After a 2-week washout of previous antihypertensive medications, eligible patients were randomized to receive either ramipril 5 mg/d in the morning (low-dose group: baseline SiDBP 90-99 mm Hg) or ramipril 10 mg/d (high-dose group: baseline SiDBP 100-109 mm Hg) for the first 4 weeks.
  • If SiDBP was > or = 90 mm Hg after 4 weeks of treatment, the dose was increased to 10 mg/d for the remaining 4 weeks in the low-dose group, and hydrochlorothiazide 12.5 mg was added to the regimen for the remaining 4 weeks in the high-dose group.
  • Secondary end points included a noninferiority analysis of the test and reference formulations with respect to the change in mean sitting systolic blood pressure (SiSBP) from baseline to week 8; SiDBP and SiSBP response rates (proportion of patients achieving an SiDBP < 90 mm Hg and SiSBP < 140 mm Hg, respectively) at 8 weeks; and changes from baseline in SiSBP, pulse wave velocity (PWV), exercise capacity, left-ventricular diastolic function (LVDF), and levels of brain natriuretic peptide (BNP) and high-sensitivity C-reactive protein (hs-CRP).
  • [MeSH-major] Antihypertensive Agents / therapeutic use. Drugs, Generic / therapeutic use. Hypertension / drug therapy. Ramipril / chemistry. Ramipril / therapeutic use
  • [MeSH-minor] Blood Pressure / drug effects. C-Reactive Protein / drug effects. Chemistry, Pharmaceutical. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Hydrochlorothiazide / therapeutic use. Korea. Male. Middle Aged. Natriuretic Peptide, Brain / blood. Natriuretic Peptide, Brain / drug effects. Prospective Studies. Severity of Illness Index. Treatment Outcome. Ventricular Function, Left / drug effects

  • Genetic Alliance. consumer health - Essential hypertension.
  • MedlinePlus Health Information. consumer health - Blood Pressure Medicines.
  • MedlinePlus Health Information. consumer health - High Blood Pressure.
  • Hazardous Substances Data Bank. HYDROCHLOROTHIAZIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19539099.001).
  • [ISSN] 0149-2918
  • [Journal-full-title] Clinical therapeutics
  • [ISO-abbreviation] Clin Ther
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antihypertensive Agents; 0 / Drugs, Generic; 0J48LPH2TH / Hydrochlorothiazide; 114471-18-0 / Natriuretic Peptide, Brain; 9007-41-4 / C-Reactive Protein; L35JN3I7SJ / Ramipril
  •  go-up   go-down


35. Costa LS, Latorre Mdo R, Silva MH, Bertolini DV, Machado DM, Pimentel SR, Marques HH: Validity and reliability of a self-efficacy expectancy scale for adherence to antiretroviral therapy for parents and carers of children and adolescents with HIV/AIDS. J Pediatr (Rio J); 2008 Jan-Feb;84(1):41-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validity and reliability of a self-efficacy expectancy scale for adherence to antiretroviral therapy for parents and carers of children and adolescents with HIV/AIDS.
  • OBJECTIVE: To validate and evaluate the reproducibility of a self-efficacy (SE) scale for adherence to antiretroviral therapy in children and adolescents with HIV/AIDS, taking into account the perspective of parents/guardians.
  • METHODS: The study was carried out at the Hospital-Dia, Centro de Referência e Treinamento em DST/AIDS (CRT/SP), in São Paulo, Brazil.
  • Data on SE were collected using the Self-Efficacy for Following Anti-Retroviral Prescription Scale, and SE scores were calculated in two different ways: factor analysis and a predefined formula.
  • Validity was tested by comparing the mean scores of a group of patients who did adhere to antiretroviral treatment with those of a group that did not (Mann-Whitney test) and by calculating the Spearman correlation coefficient for agreement between scores and clinical parameters.
  • RESULTS: The SE scale demonstrated good internal consistency (alpha = 0.87) and good reproducibility (r(icc) = 0.69 and r(icc) = 0.75).
  • In terms of validity, the SE scale was capable of differentiating adherent patients from those who did not adhere to their antiretroviral treatment (p = 0.002) and exhibited a significant correlation with CD4 counts (r = 0.28; p = 0.04).
  • CONCLUSIONS: The SE scale can be used to assess adherence to antiretroviral therapy in children and adolescents with HIV/AIDS, taking into account the perspective of parents/carers.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. Caregivers. HIV Infections / drug therapy. Parents. Patient Compliance / statistics & numerical data. Surveys and Questionnaires / standards


36. Badger C, Preston N, Seers K, Mortimer P: Benzo-pyrones for reducing and controlling lymphoedema of the limbs. Cochrane Database Syst Rev; 2004;(2):CD003140
MedlinePlus Health Information. consumer health - Lymphedema.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The standard treatment regimes include compression hosiery, skin care and exercise.
  • The use of drugs in treatment, particularly benzo-pyrones, has gained favour over the last ten years.
  • Benzo-pyrones, originally developed for use in vascular medicine, are prescribed to reduce vascular permeability and thus the amount of fluid forming in the subcutaneous tissues.
  • Advocates for this treatment method believe that, as a result of reducing filtration, the drugs have some beneficial effect on pain and discomfort in the swollen areas.
  • Proponents also claim that these drugs increase macrophage activity, encouraging the lysis of protein, which in turn reduces the formation of fibrotic tissue in the lymphoedematous limb.
  • To assess the effect of benzo-pyrones on the quality of affected tissues and on the patient's quality of life and, finally, to establish the incidence of adverse effects SEARCH STRATEGY: We searched the Cochrane Breast Cancer Group register (September 2003), the Cochrane Central Register of Controlled Trials (The Cochrane Library, Issue 4,2003), MEDLINE, EMBASE, CINAHL, UnCover, PASCAL, SIGLE, reference lists produced by The British Lymphology Society, the National Research Register (NRR) and The International Society of Lymphology congress proceedings.
  • SELECTION CRITERIA: Types of studies considered for review were randomised controlled trials testing Paroven, coumarin, Venastat, Cyclo 3 Fort or Daflon versus placebo (with both groups having or not having standard physical treatment DATA COLLECTION AND ANALYSIS: Eligibility for inclusion was confirmed by two blinded reviewers who screened the papers independently using a checklist of criteria relating to the randomisation and blinding of the trial.
  • Each tested the drug over 6 months using the same dose of drug against placebo.
  • Two were crossover trials and one a parallel group trial with a total number of 127 participants and data available for only 81 of them.
  • A single trial of Daflon (approved name) was found, lasting 6 months and involving 104 participants; once again there was insufficient information provided in the report to reach a conclusion about the effectiveness of the drug.
  • Three trials of coumarin combined with troxerutin were found and tested two different doses of the drug against each other with no placebo, however, numbers of participants in the trial groups and baseline data were not provided.
  • Five studies were conducted in India or China and they added anti-filarial dia or China and they added anti-filarial drugs to the interventions tested.
  • [MeSH-major] Benzopyrans / therapeutic use. Lymphedema / drug therapy
  • [MeSH-minor] Anticoagulants / therapeutic use. Coumarins / therapeutic use. Diosmin / therapeutic use. Extremities. Humans. Hydroxyethylrutoside / analogs & derivatives. Hydroxyethylrutoside / therapeutic use. Plant Extracts / therapeutic use. Randomized Controlled Trials as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15106192.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Benzopyrans; 0 / Coumarins; 0 / Hydroxyethylrutoside; 0 / Plant Extracts; 0 / cyclo 3; 7QM776WJ5N / Diosmin; 7Y4N11PXO8 / troxerutin
  • [Number-of-references] 80
  •  go-up   go-down


37. Mallucci C, Lellouch-Tubiana A, Salazar C, Cinalli G, Renier D, Sainte-Rose C, Pierre-Kahn A, Zerah M: The management of desmoplastic neuroepithelial tumours in childhood. Childs Nerv Syst; 2000 Jan;16(1):8-14
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of desmoplastic neuroepithelial tumours in childhood.
  • The authors report on the clinicopathological aspects of and management strategies for the group of rare, large hemispheric childhood tumours recently classified as desmoplastic infantile ganglioglioma (DIGG), desmoplastic astrocytoma of infancy (DACI) and pleomorphic xanthoastrocytoma (PXA).
  • Between 1985 and 1997, ten children (4 with DACIs, 4 with DIGGs and 2 with PXAs) with a median age of 9.5 months were operated on.
  • This led to an erroneous diagnosis in both cases of malignant grade 4 astrocytoma.
  • As a result, one patient had preoperative chemotherapy with no effect.
  • None of the patients has had any postoperative adjuvant treatment.
  • We believe that surgical excision can offer a cure and that adjuvant treatment is not necessary.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Ganglioglioma / diagnosis
  • [MeSH-minor] Biopsy. Cerebral Cortex / pathology. Cerebral Cortex / surgery. Child. Child, Preschool. Diagnostic Errors. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Prognosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10672423.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] GERMANY
  •  go-up   go-down






Advertisement